Scientists Discover Potential Path to Treating Down Syndrome
Gizmodo • • health
Key Points:
- Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have developed a modified CRISPR/Cas9 technique that can silence the extra 21st chromosome responsible for Down syndrome by integrating the XIST gene into cells, potentially paving the way for a genetic treatment.
- The new method significantly improves the rate of XIST integration, achieving silencing in about 20% of 40% of trisomy 21 cell lines, and specifically targets only one chromosome copy to minimize side effects.
- Down syndrome currently has no cure, with affected individuals facing developmental delays, intellectual disability, and a reduced lifespan; silencing the extra chromosome could mitigate these effects.
- While promising, this research is still at an early stage, requiring further studies to ensure safety, optimize delivery, and assess effectiveness in animal models before human clinical trials can begin.
- The team is optimistic that their approach could eventually lead to the first genuine treatment for Down syndrome, potentially transforming outcomes for those with this common genetic condition.
